Oxford-firm Physiomics study boosted by outcome of cancer treatment trial
Physiomics shares have surged following the completion of a Partner study.
The Oxford-based oncology consultancy uses mathematical models to support the development of cancer treatment and personalised medicine solutions.
The Partner study, which has now finished, was an observational trial run by the Portsmouth Technology Trials Unit funded by a £150,000 grant from the National Institute for Health Research (NIHR).
READ MORE: Physiomics’ shares jump following Cancer Research UK agreement
Analysis of trial data confirms the ability of the tool to predict levels and timing of episodes of low white blood cell count associated with use of docetaxel.
Trial data further suggests there is potential for the tool to be used to predict the effect of GCSF ( granulocyte-colony stimulating factor) , a drug commonly used to increase white blood cell count during chemotherapy.
The NIHR funded research builds on work completed under two previous grants with data being used to support development of a personalised dosing tool for docetaxel in prostate cancer
Physiomics shares jumped 87% to 5.81 pence each in London on Monday morning.
Dr Jim Millen, CEO commented : "I believe that the PARTNER study, as the culmination of several years of grant funded work, offers a significant opportunity for Physiomics to engage in the emerging personalised dosing space, either alone or in partnership with other complementary technologies. We'll be actively following up the areas noted above and will provide an update to shareholders before the end of Q1 2023."
